Entera Bio Ltd. announced that several Board members, including the Chairman, made open market purchases of the Company’s shares. Purchases were made by Chairman Geno J. Germano, Director Steven D. Rubin, Director Haya Taitel, and Director Sean Ellis. All transactions were compliant with securities laws and insider trading policies. Entera Bio focuses on developing oral peptide and protein replacement therapies for medical needs. Their most advanced product candidate, EB613, showed positive results in a Phase 2 study for osteoporosis treatment. The company is also working on therapies for hypoparathyroidism, obesity, and rare malabsorption conditions.

Read more at GlobeNewswire: Entera Bio Announces Open Market Purchases of Company Stock